INTEGRA LIFESCIENCES HOLDINGS CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IART in the last 30 days.
See all $IART insider activity →RTX secured a $24.4B Navy contract. Lilly's Jaypirca gained FDA approval. Integra cut 2026 revenue guidance due to flooding. Trilogy closed $35.6M equity investment. Nasdaq rose 1.19%, Dow fell 1.26% weekly.
Nasdaq Composite hit a new high at 27,190.86, up 1.19%, while the Dow Jones Industrial Average fell to 51,176.96, down 1.26% for the week. The S&P 500 gained 0.73% to 7,722.72, and the Russell 2000 rose 0.94% to 2,832.90. Gold, silver, and copper prices advanced, while crude oil fell and Treasury yields increased. Key companies mentioned include RTX, LLY, IBM, IART, and TMQ.
BMO Capital reduced its price target for Integra LifeSciences (NASDAQ:IART) to $15 from $18, citing lower guidance due to flooding at a key facility. The stock has fallen 22% in the past week. Despite near-term challenges, InvestingPro values the stock at $19.60. The company's Q2 2026 earnings beat estimates, but shares declined on cautious future outlook.
Over the past 7 days, AlphAI's AI scored 21 news stories mentioning IART (INTEGRA LIFESCIENCES HOLDINGS CORP). Coverage has skewed bearish: 0 bullish, 0 neutral, and 21 bearish.
Recent IART coverage spans financial news, market movers and earnings.
Guidance cut reflects flood‑related revenue loss.
Guidance reduction signals weaker outlook and potential cash‑flow strain.
Analyst downgrade due to operational disruption and weaker guidance.
Guidance downgrade may weigh on the share price.
The preliminary results and refinancing plan triggered a sharp sell‑off, suggesting weak guidance and heightened debt concerns.
AlphAI scores every news story that mentions IART with an AI model for sentiment and relevance, and aggregates insider trades from INTEGRA LIFESCIENCES HOLDINGS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
RTX secured a $24.4B Navy contract. Lilly's Jaypirca gained FDA approval. Integra cut 2026 revenue guidance due to flooding. Trilogy closed $35.6M equity investment. Nasdaq rose 1.19%, Dow fell 1.26% weekly.
2 min readNasdaq Composite hit a new high at 27,190.86, up 1.19%, while the Dow Jones Industrial Average fell to 51,176.96, down 1.26% for the week. The S&P 500 gained 0.73% to 7,722.72, and the Russell 2000 rose 0.94% to 2,832.90. Gold, silver, and copper prices advanced, while crude oil fell and Treasury yields increased. Key companies mentioned include RTX, LLY, IBM, IART, and TMQ.
3 min readBMO Capital reduced its price target for Integra LifeSciences (NASDAQ:IART) to $15 from $18, citing lower guidance due to flooding at a key facility. The stock has fallen 22% in the past week. Despite near-term challenges, InvestingPro values the stock at $19.60. The company's Q2 2026 earnings beat estimates, but shares declined on cautious future outlook.
2 min readNasdaq Composite gained 0.44% for the week, driven by tech stocks, while Dow Jones and Russell 2000 declined. RTX secured a $24.4B contract, IART lowered FY26 guidance due to flooding, TMQ reported Q3 earnings, PECO increased acquisition guidance, and AXGN completed an acquisition. VIX fell, crude oil dropped, and 10-year Treasury yield rose.
3 min readIntegra LifeSciences (IART) shares fell 21% after releasing preliminary Q3 results and announcing a $600M debt refinancing. The company specializes in neurosurgery, surgical tools, and regenerative technologies.
2 min readU.S. stock indices rose midday on Oct. 2, with the Nasdaq hitting a record high. Tesla gained over 5% on strong delivery numbers, while ON Semiconductor and Synaptics rose on a revised merger deal. Integra LifeSciences fell after lowering guidance. Weak jobs data reduced Fed rate hike expectations, boosting markets.
2 min readTesla shares rose 5% after reporting 486,532 vehicle deliveries for Q3 2026. Seagate and Western Digital fell 13% and 12% respectively due to competition concerns. Nike shares dropped 5.6% after missing revenue targets and forecasting a sales decline. Integra Lifesciences cut its 2026 revenue guidance due to flooding. Applied Digital expanded AI infrastructure in North Dakota.
3 min readIntegra LifeSciences (IART) cut its FY26 adjusted EPS and revenue forecast due to Cincinnati flood damage, now expecting $2.30-$2.40 EPS and $1.634B-$1.654B revenue. Q3 revenue is estimated to be $410M-$412M. The company plans a $600M debt refinancing to extend maturities and maintain flexibility.
2 min readIntegra LifeSciences (IART) lowered its 2026 guidance due to flooding at its Cincinnati facility, reducing revenue and EPS forecasts. Q3 revenue is expected at $410M-$412M, with full-year revenue now projected at $1.634B-$1.654B. The company estimates a $7M Q3 and $15M-$20M Q4 revenue impact. Full operations are expected to resume by Q2 2027, with insurance covering some losses. CEO Stuart Essig anticipates Q3 operating cash flow of over $85M and full-year cash flow of $190M-$200M.
2 min readIntegra LifeSciences (IART) launched a $600M 7-year Senior Secured Term Loan B for refinancing existing debt. The company aims to complete the transaction, subject to market conditions, to extend maturities and maintain financial flexibility, according to its CFO.
1 min read
